Resveratrol Alleviates Hepatic Fibrosis in Associated with Decreased Endoplasmic Reticulum Stress-Mediated Apoptosis and Inflammation

Zhenyu Ma1, Lulu Sheng2, Juan Li3, Jianmin Qian1, Gang Wu1, Zhengxin Wang1,6 and Yi Zhang4,5,6

Abstract——Hepatic fibrosis (HF) is the typical response to chronic liver disease and is characterized by deposition of abundant extracellular matrix. The aim of the present study was to investigate the protective effect of resveratrol (RSV) in a CCl4-induced rat model of HF. We demonstrate that the administration of RSV effectively improves liver function and ameliorates liver fibrosis by reducing collagen deposition and reversing the expression of COL1A1 and PPAR-γ. Treatment efficacy of RSV could be attributed to reversed epithelial-mesenchymal transition progress with upregulated expression of E-cadherin and downregulated N-cadherin, vimentin, and α-SMA. Moreover, RSV significantly decreased the levels of endoplasmic reticulum stress (ERS)-related proteins CHOP; Bip; cleaved caspase-3, caspase-7, and caspase-12; Bax; and Bak while promotes the expression of anti-apoptosis protein Bcl2. The important role of ERS in HF was confirmed by using 4-PBA, an ERS inhibitor, which markedly ameliorated CCl4-induced HF. Further, mechanistic studies demonstrated that RSV significantly decreased CCl4-induced transforming growth factor-β synthesis and inflammatory factor (tumor necrosis factor-α and interleukin-6) expression and reduced the inflammation of hepatic stellate cells by inhibiting the NF-κB pathway in vivo and in vitro. In conclusion, the results suggested that RSV ameliorated HF in associated with decreased ERS-induced apoptosis and inflammation in rats.

KEY WORDS: hepatic fibrosis; resveratrol; endoplasmic reticulum stress; inflammation
INTRODUCTION

Hepatic fibrosis (HF) is a serious health problem all over the world, contributing to the pathological progression of chronic liver disease to cirrhosis and cancer. Currently, no effective therapy was found to completely reverse the disease, while interventions from the early stage may largely block the progression of HF [1].

With the stimulation of tissue injury, quiescent hepatic stellate cells (HSCs) are activated and transdifferentiate into myofibroblasts, which are responsible for the excessive deposition of extracellular matrix (ECM), especially interstitial collagen [2]. HSCs are considered to be the main target of a number of profibrotic factors, including transforming growth factor (TGF)-β [3].

The endoplasmic reticulum (ER) is the intracellular organelle responsible for the synthesis, folding, trafficking, and maturation of proteins. The ER interacts with other intracellular organelles, including mitochondria, the Golgi apparatus, endosomes, peroxisomes, and the plasma membrane [4]. The liver synthesizes a large number of proteins and lipids, and hepatocytes have well-functioning ERs with appropriate adaptive capability. Pathological stimuli, including inflammation and oxidative stress, can disrupt the function of the ER, resulting in the aggregation of misfolded proteins in the ER cavity, which causes cell homeostasis imbalance and hepatic dysfunction [5]. Preclinical studies have suggested that upregulation of ER stress (ERS)-related proteins, including binding immunoglobulin protein (BIP), Bcl-2 associated X protein (Bax), Bcl-2 homologous antagonist/killer (Bak), and C/EBP homologous protein (CHOP), occurs in animal models of HF [6, 7]. CHOP may lead to HF by increasing the expression of fibrotropic factors, including α-smooth muscle actin (α-SMA), TGF-β, and collagen [8]. In addition, a number of studies have reported that ERS promotes HF progression by activating HSCs [9, 10]. In a CCl₄-induced rat model of HF, the protein and mRNA expression levels of Tribbles homolog 3 (TRB3) and CHOP were upregulated, which suggested that ERS may induce hepatocytes apoptosis via TRB3 and CHOP [11].

Resveratrol (RSV) is a natural polyphenolic compound, containing an Astragalus membranaceus structure and non-flavonoids, and is primarily found in red wine and peanuts. Recently, it has been reported that RSV displays antitumor, antioxidant, anti-inflammatory, hypoglycemic, analgesic, and antiasthmatic effects [12]. It has also been reported that RSV displays protective effects against cardiovascular [13] and liver disease including CCl₄-induced HF [14], but the mechanisms remain unclear. In the present study, the specific mechanisms underlying the effects of RSV on HF, and whether RSV inhibits ERS-mediated apoptosis and inflammation in a rat model of HF were investigated.

MATERIALS AND METHODS

Animals

Sprague–Dawley male rats (age, 3–4 weeks; weight, 200–250 g) were purchased from Shanghai SLAC Experimental Animal Co., Ltd. Animals were housed at 22 ± 1 °C, with 50 ± 1% humidity, 12 h light/dark cycles, and free access to water and food (standard diet). The present study was approved by the Bioethics Committee of Huashan Hospital, Fudan University, Shanghai.

HF Model Establishment and Primary HSC Isolation

Rats were anaesthetized by intraperitoneal injection of 0.1% sodium pentobarbital (40 mg/kg). Subsequently, the rats were subcutaneously injected with 40% CCl₄ (Beijing Beihua Fine Chemicals Co., China) dissolved in olive oil suspension (Beyotime Biotechnology, Jiangsu Province, China; 2 ml/kg twice a week) and intragastrically administer with 0.5% carboxymethylcellulose (CMC) sodium salt (Sigma-Aldrich, St. Louis, MO) once a day for 12 weeks with or without RSV (Sigma-Aldrich) daily treatment intragastrically for 12 weeks. The control group was treated olive oil and was orally administered sodium CMC. In some experiments, the ERS inhibitor, 4-PBA (Sigma-Aldrich), was intraperitoneally administrated (10 mg/kg). At the end of the 12 weeks, rats were anesthetized with 40 mg/kg sodium pentobarbital, and 5–10 ml blood was collected from the heart; following blood collection, rats were euthanized by cervical dislocation, and liver tissue samples were collected. To isolate HSCs in the indicated time, livers were digested by collagenase/pronase. The HSCs were obtained from the non-parenchymal cell fraction by density-gradient centrifugation using 28% Nycodenz (Nycemed Pharma, Oslo, Norway) and fluorescence-activated cell sorting using their typical retinoid fluorescence.
Liver Function Analysis

The serum of rats was collected to measure the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) using a biochemical analyzer (Hitachi, Japan); alkaline phosphatase (ALP) and γ-glutamyl transpeptidase (GGT) were assessed using commercial kits purchased from Westang Company (Shanghai, China).

Cell Culture and Treatment

The immortalized human HSC cell line LX-2 (provided by Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University) were routinely cultured in DMEM medium containing 10% fetal bovine serum. Cells were treated with or without various concentrations of RSV and stimulated with TGF-β for 24 h.

Histological Examination

Liver tissues were fixed, embedded in paraffin, and cut into 5-μm-thick sections. Subsequently, sections were dewaxed and stained with Hematoxylin & Eosin (H&E), Sirius red, or Masson’s trichrome. Severity of liver steatosis was determined according to the 2006 criteria of the Chinese Medical Association Committee of Fatty Liver Disease and Nouchi et al. [15, 16]. Steatosis was graded based on the extent of parenchyma involved: grade 0, no hepatocytes involved; grade 1, < 30% of hepatocytes involved; grade 2, 30–50% of hepatocytes involved; grade 3, 51–75% of hepatocytes involved; and grade 4, > 75% of hepatocytes involved. The stage of HF was graded using the METAVIR scale [17], which grades fibrosis on a 5-point scale: grade 0, no fibrosis; grade 1, portal fibrosis without septa; grade 2, portal fibrosis with a few septa; grade 3, numerous septa without cirrhosis; and grade 4, cirrhosis. For the quantification of collagen deposition in Sirius red or Masson’s trichrome staining, six different high power fields from each section were randomly chosen and examined using computer-assisted image analysis. The optical density and color area percentage of collagen fibers were assessed. Sections were observed under a light microscope and analyzed by a pathologist who was blinded to the different treatments.

Quantitative PCR (qPCR)

Total RNA was extracted from liver tissues using TRIzol® reagent (Thermo Fisher Scientific, Bremen, Germany). Total RNA (0.5 μg) in 10 μl volume was reverse transcribed into cDNA using the RevertAid™ First Strand cDNA Synthesis kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. The reverse transcription steps included 37 °C for 15 min, 85 °C for 5 min, and a termination step at 4 °C. qPCR was performed using the SYBR Premix Ex Taq kit (Takara Bio, Shiga, Japan) and the applied biosystem (Thermo Fisher Scientific) according to the manufacturer’s protocol. The primer pairs used for qPCR are presented in Table 1. The following thermocycling conditions were used for qPCR: after initiation (30 s at 95 °C), amplification was performed for 45 cycles including denaturation (5 s at 95 °C), annealing (30 s at 55 °C), and extension (60 s at 72 °C). mRNA expression levels were quantified using the 2 − ΔΔCq method and normalized to the internal reference gene GAPDH.

ELISA

Liver tissue samples were analyzed using the Westang ELISA kit according to the manufacturer’s protocol. Briefly, the tissue lysate supernatant and standard were transferred to an ELISA plate and mixed for 40 min at 37 °C. After washing, the first anti-working liquid, enzyme-labeled antibody working liquid, and substrate

| Name             | Sequence                                      |
|------------------|-----------------------------------------------|
| GAPDH forward    | 5'-AGGTCCGGTGTAACGCCATTTGTT-3'                |
| GAPDH reverse    | 5'-GGGGTTTCGGACTGCAACA-3'                    |
| TGF-β forward    | 5'-CTTCGTACAGCAGCAGCAGC-3'                   |
| TGF-β reverse    | 5'-CGGGTGACCTCTTTTGGGCTA-3'                  |
| COL1A1 forward  | 5'-TGAGCATGCGCCACAAGAAGAAG-3'                |
| COL1A1 reverse  | 5'-CTCTTGGATAGGCCGGC-3'                      |
| TNF-α forward    | 5'-ATGACGACAGAAGATGATG-3'                    |
| TNF-α reverse    | 5'-TACAGGGTATGTCACTGCAAT-3'                  |
| PPAR-γ forward  | 5'-ATTCTGGCCCCACACTCTGCG-3'                  |
| PPAR-γ reverse  | 5'-TGAAAGCGTATGCTTATCITC-3'                  |
| IL-6 forward     | 5'-CCTGGAGAGAGAGACTCTACAGCAGCA-3'            |
| IL-6 reverse     | 5'-TCAGTGCATCAGGCCACGGTTC-3'                 |
working liquid were added to each well. Subsequently, the reaction was terminated using a termination solution, and the absorbance of each well was measured at a wavelength of 450 nm. Sample contents were determined using an ELISA standard curve, which consisted of the concentration gradient of the standard substance on the x axis plotted against the optical density value on the y axis.

**Western Blot**

Liver tissues or cells were lysed, and total protein was quantified using a bicinchoninic acid assay (Beyotime Biotechnology). Proteins (20 µg) were separated via 12% SDS-PAGE and transferred onto polyvinylidene difluoride membranes at 300 mA for 120 min. The membranes were blocked with 5% BSA (Beyotime Biotechnology) for 1 h at room temperature. Subsequently, the membranes were incubated overnight at 4 °C with the following primary antibodies diluted 1,000-fold that recognized COL1A1; PPAR-γ; E-cadherin; N-cadherin; vimentin; α-SMA; CHOP; BIP; cleaved caspase-3, caspase-7, and caspase-12; Bcl2; Bax; Bak; p-p65-NF-κB; p65-NF-κB; p-IκBα; IκBα; and β-actin (all from Cell Signaling, USA or Abcam, UK). Following primary incubation, the membranes were washed with TBS Tween 20 (1%) and incubated with a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:10,000) at room temperature for 1 h. Protein bands were visualized using an enhanced chemiluminescence system (Thermo Fisher Scientific). Protein band intensities were examined using Image-Pro Plus software (version 6.0; Media Cybernetics, MD, USA), and all values were normalized to β-actin. Data of liver tissues and cultured cells are calculated from three independent experiments.

**Statistical Analysis**

Data are expressed as the mean ± standard deviation (SD) and analyzed by SPSS 13.0 (SPSS, Chicago, IL, USA). Survival analysis was performed using the Kaplan–Meier method, and survival curves were compared using Bonferroni’s test. Comparisons between two groups were analyzed using the Student’s t-test. Multiple comparisons were analyzed using one-way ANOVA followed by Tukey’s post hoc test. A p < 0.05 was considered to indicate a statistically significant difference.

**RESULTS**

**RSV Effectively Decreases the Liver Function Index in a CCl₄-Induced Rat Model of HF**

The chemical structure of RSV is presented in Fig. 1A. The results indicated that RSV significantly increased the survival rate in the rat of CCl₄ group (Fig. 1B). To further explore the protective effect of RSV on the liver, liver function indices, including ALT, AST, ALP, and γ-GGT, in each group were measured. Compared with the control group, liver function indices were significantly increased in the CCl₄ group, and RSV treatment, particularly with a dose of 30 mg/kg, significantly reversed CCl₄-induced effects on liver function (Fig. 1C-F).

**RSV Reduces CCl₄-Induced Fat and Collagen Deposition and Ameliorates CCl₄-Induced Liver Fibrosis**

Pathological analysis was performed to evaluate the degree of hepatic injury and fibrosis induced by CCl₄ in rats. The structure of hepatic lobules was disordered in the CCl₄ group, which was indicated by hepatocyte steatosis, necrosis, inflammatory cell infiltration, hepatic lobule separation by collagen fibers, and a large amount of collagen fiber deposition in the portal area. RSV treatment restored the hepatic lobule structure, necrosis, inflammatory cell infiltration, and fibrous tissue proliferation in the portal canal area (Fig. 2A). Moreover, the 10, 20, and 30 mg/kg of RSV significantly decreased the interstitial collagen area dose dependently using Masson’s trichrome and Sirius red staining (Fig. 2A). To further study role of RSV on liver fibrosis, we then evaluated the levels of COL1A1 and PPAR-γ in livers. As shown in Fig. 2B and C, RSV treatment significantly reversed the expression of COL1A1 and PPAR-γ in both mRNA and protein levels. These results suggested that RSV reduces CCl₄-induced collagen deposition and liver fibrosis.

**RSV Reduces CCl₄-Induced Epithelial-Mesenchymal Transition (EMT) and ERS in Rats**

EMT and ERS are associated with HF. Western blotting was performed to measure the expression levels of EMT- and ERS-related proteins. The expression of E-cadherin (epithelial marker) was decreased, whereas
levels of N-cadherin, vimentin, and α-SMA (mesenchymal markers) were increased in the CCl4 group; RSV treatment significantly reversed their expression (Fig. 3A). In addition, RSV treatment largely decreased the levels of ERS-related proteins CHOP and BIP, and apoptosis-related proteins cleaved caspase 3, 7, 12, Bax and Bak, whereas promoted the expression of anti-apoptosis protein Bcl2. To further investigate whether ERS participated in CCl4-induced HF, 4-PBA (an ERS inhibitor) was administrated by intraperitoneal injection. As shown in Fig. 3C, pathological analysis indicated that 4-PBA markedly ameliorated the structure of
hepatic lobules, with low levels of necrosis, inflammatory cell infiltration, and collagen deposition in the liver of CCl4 treated rats. The results indicated that RSV reduces CCl4-induced EMT and ERS.

RSV Significantly Reduces CCl4-Induced TGF-β Synthesis and Inflammatory Factor Expression

To investigate the involvement of TGF-β during HF, the expression levels of TGF-β in the liver were detected using ELISA and qPCR. Secretion and mRNA levels of TGF-β in the liver were significantly increased in the CCl4 group compared with the control group, and RSV treatment decreased CCl4-induced TGF-β levels, which was significantly attenuated by 30 mg/kg RSV (Fig. 4A and B). Furthermore, serum levels of inflammatory factors tumor necrosis factor (TNF)-α and interleukin (IL)-6 were reversed by RSV treatment (Fig. 4C). As HSC activation plays a vital role in HF, we isolated liver HSCs 1 month after CCl4 induction in each group and found that RSV treatment greatly decreased the mRNA levels of TNF-α and IL-6 in HSCs as compared with that of CCl4-treated rats (Fig. 4D). These data demonstrated that RSV significantly reduces CCl4-induced TGF-β synthesis and inflammatory factor expression in livers and HSCs.

RSV Significantly Reduces the Inflammation of HSCs by Inhibiting the NF-κB Pathway In Vitro

To further dissect the cellular mechanisms involved in the protective role of RSV in HSCs, we set out to induce hepatic lobules, with low levels of necrosis, inflammatory cell infiltration, and collagen deposition in the liver of CCl4 treated rats. The results indicated that RSV reduces CCl4-induced EMT and ERS.

RSV Significantly Reduces CCl4-Induced TGF-β Synthesis and Inflammatory Factor Expression

To investigate the involvement of TGF-β during HF, the expression levels of TGF-β in the liver were detected using ELISA and qPCR. Secretion and mRNA levels of TGF-β in the liver were significantly increased in the CCl4 group compared with the control group, and RSV treatment decreased CCl4-induced TGF-β levels, which was significantly attenuated by 30 mg/kg RSV (Fig. 4A and B). Furthermore, serum levels of inflammatory factors tumor necrosis factor (TNF)-α and interleukin (IL)-6 were reversed by RSV treatment (Fig. 4C). As HSC activation plays a vital role in HF, we isolated liver HSCs 1 month after CCl4 induction in each group and found that RSV treatment greatly decreased the mRNA levels of TNF-α and IL-6 in HSCs as compared with that of CCl4-treated rats (Fig. 4D). These data demonstrated that RSV significantly reduces CCl4-induced TGF-β synthesis and inflammatory factor expression in livers and HSCs.

RSV Significantly Reduces the Inflammation of HSCs by Inhibiting the NF-κB Pathway In Vitro

To further dissect the cellular mechanisms involved in the protective role of RSV in HSCs, we set out to induce hepatic lobules, with low levels of necrosis, inflammatory cell infiltration, and collagen deposition in the liver of CCl4 treated rats. The results indicated that RSV reduces CCl4-induced EMT and ERS.

RSV Significantly Reduces CCl4-Induced TGF-β Synthesis and Inflammatory Factor Expression

To investigate the involvement of TGF-β during HF, the expression levels of TGF-β in the liver were detected using ELISA and qPCR. Secretion and mRNA levels of TGF-β in the liver were significantly increased in the CCl4 group compared with the control group, and RSV treatment decreased CCl4-induced TGF-β levels, which was significantly attenuated by 30 mg/kg RSV (Fig. 4A and B). Furthermore, serum levels of inflammatory factors tumor necrosis factor (TNF)-α and interleukin (IL)-6 were reversed by RSV treatment (Fig. 4C). As HSC activation plays a vital role in HF, we isolated liver HSCs 1 month after CCl4 induction in each group and found that RSV treatment greatly decreased the mRNA levels of TNF-α and IL-6 in HSCs as compared with that of CCl4-treated rats (Fig. 4D). These data demonstrated that RSV significantly reduces CCl4-induced TGF-β synthesis and inflammatory factor expression in livers and HSCs.
the activation of human HSC cell line LX-2 with TGF-β in vitro for 24 h. As shown in Fig. 5A and B, mRNA levels in HSCs and secretion levels in the supernatant of TNF-α and IL-6 after TGF-β induction were greatly increased, whereas RSV treatment significantly decreased the levels of inflammatory factors. Moreover, RSV treatments abolished the phosphorylation of p65- NF-κB and IκBα in a dose-dependent manner (Fig. 5C). Thus, RSV significantly reduces the HSC inflammation by inhibiting the NF-κB pathway in vitro.
Fig. 4 Effect of RSV on CCl₄-induced TGF-β synthesis and inflammatory factor expression. Rat HF models were established with or without RSV treatment. Peripheral blood and liver tissues were collected after 3 months. HSCs were isolated from livers 1 month after establishment. A mRNA expression levels of TGF-β in liver tissue were measured by qPCR. B Secretory TGF-β levels in livers were measured by ELISA. C Serum levels of inflammatory factors TNF-α and IL-6 were measured by ELISA. D mRNA levels of TNF-α and IL-6 in liver HSCs were measured by qPCR. A–D Results from three independent experiments are shown as mean ± SD (n=6 rats per group). More than 12 rats were used for each experiment to make sure that at least 3 rats were survived in the CCl₄ group 3 months after HF development. *p < 0.05, **p < 0.01, and ***p < 0.001.
DISCUSSION

HF is the most common pathological feature of chronic liver disease; however, a limited number of effective drugs are available within clinics [18]. RSV is a polyphenolic compound and has been used for the treatment of atherosclerosis, as well as cardiovascular and cerebrovascular diseases [13]. Furthermore, previous studies have reported that RSV effectively inhibits HF in rats; however, the specific mechanism of action and effective dosage has not been identified [19, 20]. In the present study, rats were administered with CCl4 and different concentrations of RSV. After 12 weeks, liver function was measured to evaluate the degree of liver damage. The results indicated that compared with the control group, the liver function was severely impaired in the CCl4 group, which was characterized by degeneration and necrosis of hepatocytes, and abnormal deposition of collagen. Following treatment with RSV, the liver function was significantly improved, and the serum indices, including ALT, AST, ALP, and γ-GGT, were significantly decreased. Furthermore, the degeneration and necrosis of hepatocytes were significantly reduced, suggesting that RSV may inhibit HF progression.

Recent studies have demonstrated that HSC activation is essential in the pathogenesis of liver fibrosis and abnormal activated EMT is suggested to potentially promote HSC activation [21]. In the present study, the expression of E-cadherin (epithelial marker) in the CCl4 group was downregulated compared with the control group, while the expression of N-cadherin, vimentin, and α-SMA (mesenchymal markers) was upregulated.

Fig. 5 RSV reduces LX-2 cell inflammation by inhibiting the NF-κB pathway in vitro. LX-2 cells were treated with or without RSV (10, 20, or 50 µM) and stimulated with TGF-β for 24 h. mRNA levels and supernatant levels of TNF-α and IL-6 were measured by qPCR (A) and ELISA (B). C Levels of p-p65-NF-κB, p65-NF-κB, p-IκBα, IκBα, and β-actin were measured by western blot. Representative images were shown on the left and summarized results are on the right. A–C Results from three independent experiments are shown as mean ± SD (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001.
The results indicated that the HSCs may undergo EMT, which was demonstrated by the loss of epithelial markers and the gain of mesenchymal markers, to transform into fibroblasts or mesenchymal cells following CCl4 stimulation. However, treatment with RSV increased the expression of E-cadherin and decreased the expression of N-cadherin, vimentin, and α-SMA compared with the CCl4 group, which indicated that RSV could reduce CCl4-induced EMT.

Caspases participate ERS-induced apoptosis. Previous studies have reported that the caspase-12 signaling pathway is closely associated with the development of cholestatic HF and non-alcoholic HF [22, 23]. In response to ERS, caspase-7 rapidly cleaves and activates caspase-12, leading to the activation of downstream caspases, including caspase-3 [24]. Importantly, the balance of proapoptotic Bax, Bak, and antiapoptotic Bcl-2 proteins in mitochondria determine the fate of cells. Tian et al. demonstrated that the protein expression of Bcl-2 in the liver tissue was downregulated, while levels of Bak and Bax were upregulated in rats with CCl4 stimulation [7]. In the present study, RSV treatment largely decreased the expression levels of ERS-related proteins CHOP; BIP; cleaved caspase-3, caspase-7, and caspase-12; Bax; and Bak while promotes the expression of anti-apoptosis protein Bcl2, indicating that RSV is protective in ERS-induced apoptosis.

The occurrence and development of HF are regulated by different cytokines, including TGF-β and NF-κB [22]. Unfolded protein response-induced apoptosis can lead to TGF-β secretion, which in turn promotes HF [25]. ERS participates in HF by regulating the release of inflammatory cytokines such as TNF-α and IL-6, which are the main factors inducing HF [26, 27]. Moreover, the TGF-β signaling pathway not only serves a key role in the HF process, but is also involved in the activation and transformation of HSCs [28]. Wang et al. recently indicated that TGF-β-mediated NF-κB pathway plays an important role in HSC activation and HF both in vivo and in vitro, which can be restored by treatment of the active components of Schisandra chinensis, a traditional Chinese medicine [29]. The present study suggested that RSV inhibited the release of TGF-β and subsequent systemic and HSC inflammation in associated with decreased ERS-induced apoptosis and inflammation via NF-κB dependent manner in HF rats.

In conclusion, our findings demonstrate that RSV effectively ameliorates the severity of CCl4-induced HF in associated with the decreased EMT and ERS in livers. Mechanistically, treatment of RSV inhibits the systemic and HSC inflammation in a NF-κB dependent manner. Currently, we are still working on optimizing the treatment of RSV in CCL4-induced liver fibrosis, and we believe the work will be benefit to disclose the protective window of time of RSV and clarify the molecular and cellular mechanisms in future.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at https://doi.org/10.1007/s10753-021-01586-w.

AUTHOR CONTRIBUTION

ZM and LS established animal models; performed cell line stimulation, western blot, and ELISA experiment; wrote the manuscript; and acquired the data. JL performed the morphological staining experiments, analyzed the experimental data, and revised the manuscript. JQ and GW performed the qPCR experiment. YZ and ZW designed the study and revised the manuscript. ZW funded this research. All authors read and approved the final submission.

FUNDING

The present study was supported by the National Natural Science Foundation of China (grant no. 81873874) and the National Science and Technology Major Projects (grant nos. 2017ZX10203205-002-004 and 2017ZX10203205-003-003).

AVAILABILITY OF DATA AND MATERIALS

All data used during the study are available through contacting the corresponding author by request.

DECLARATIONS

Ethics Approval and Consent to Participate The present study was approved by the Bioethics Committee of Huashan Hospital, Fudan University, Shanghai.

Consent for Publication We state that the manuscript has not been published in any form; that it is not considered for publication elsewhere; and that its publication has been approved by all co-authors, if any.

Competing Interests The authors declare no competing interests.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Meirelles Junior, R.F., P. Salvalaggio, M.B. Rezende, A.S. Evangelista, B.D. Guardia, C.E. Matiello, D.B. Neves, et al. 2015. Liver transplantation: History outcomes and perspectives. Einstein (Sao Paulo) 13: 149–152.

2. Fan, Y. Y., W. Ding, C. Zhang, L. Fu, D. X. Xu, and X. Chen. 2019. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3. International Immunopharmacology 57: 105911.

3. Yang, F., H. Li, Y. Li, Y. Hao, C. Wang, P. Jia, X. Chen, et al. 2021. Crosstalk between hepatic stellate cells and surrounding cells in hepatic fibrosis. International Immunopharmacology 99: 108051.

4. Pavlovic, N., and F. Heindryckx. 2021. Targeting ER stress in the hepatic microenvironment. The FEBS Journal.

5. Baiceanu, A., P. Mesdom, M. Lagouge, and F. Foufelle. 2016. Alpha-1 antitrypsin. Reviews Endocrinology 12: 710–722.

6. Shen, Y., P. Ballar, and S. Fang. 2006. Ubiquitin ligase gp78 increases solubility and facilitates degradation of the Z variant of alpha-1-antitrypsin. Biochemical and Biophysical Research Communications 349: 1285–1293.

7. Tian, H., L. Liu, Z. Li, W. Liu, Z. Sun, Y. Xu, S. Wang, et al. 2019. Chinese medicine CGA formula ameliorates liver fibrosis induced by carbon tetrachloride involving inhibition of hepatic apoptosis in rats. Journal of Ethnopharmacology 232: 227–235.

8. Gao, P., B. Yang, H.Y. Yu, R.R. Meng, and J.Y. Si. 2017. Curvedilol alleviates the biliary cirrhosis through inhibiting the endoplasmic reticulum stress. European Review for Medical and Pharmacological Sciences 21: 5813–5820.

9. Ma, Y., Y. Li, H. Zhang, Y. Wang, C. Wu, and W. Huang. 2020. Malvidin induces hepatic stellate cell apoptosis via the endoplasmic reticulum stress pathway and mitochondrial pathway. Food Science & Nutrition 8: 5095–5106.

10. Wu, J.S., V. Chiu, C.C. Lan, M.C. Wang, I.S. Tseng, C.Y. Kuo, and P.C. Hsieh. 2020. Chrysophanol prevents lipopolysaccharide-induced hepatic stellate cell activation by upregulating apoptosis, oxidative stress, and the unfolded protein response. Evidence-Based Complementary and Alternative Medicine 2020: 8426051.

11. Maiers, J.L., E. Costallari, M. Mushref, T.M. deAssuncao, H. Li, N. Jalan-Sakrikar, R.C. Huebert, et al. 2017. The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice. Hepatology 65: 983–998.

12. Tian, B., and J. Liu. 2020. Resveratrol: A review of plant sources synthesis stability modification and food application. Journal of the Science of Food and Agriculture 100: 1392–1404.

13. Huang, B., W. Zhang, L. Wei, S. Chen, T. Wang, and R. Fu. 2018. Resveratrol down-regulates endothelin type B receptors in vascular smooth muscle cells via Sirt1/ERK1/2/NF-kappaB small-kal CysRic-liC signaling pathways. European Journal of Pharmacology 840: 44–49.

14. Chavez, E., K. Reyes-Gordillo, J. Segovia, M. Shibayama, V. Tsutsumi, P. Vergara, M.G. Moreno, et al. 2008. Resveratrol prevents fibrosis NF-kappaB activation and TGF-beta increases induced by chronic CC14 treatment in rats. Journal of Applied Toxicology 28: 35–43.

15. Zeng, M.D., J.G. Fan, L.G. Lu, Y.M. Li, C.W. Chen, B.Y. Wang, Y.M. Mao, et al. 2008. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. Journal of Digestive Diseases 9: 108–112.

16. Nouchi, T., T.M. Worner, S. Sato, and C.S. Lieber. 1987. Serum procollagen type III N-terminal peptides and laminin P1 peptide in alcoholic liver disease. Alcoholism Clinical and Experimental Research 11: 287–291.

17. Kim, K.M., W.B. Choi, S.H. Park, E. Yu, S.G. Lee, Y.S. Lim, H.C. Lee, et al. 2007. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: A prospective study of living related potential liver donors. Journal of Gastroenterology 42: 382–388.

18. Shan, L., Z. Li, L. Ci, C. Shuai, X. Lv, and J. Li. 2019. Research progress on the anti-hepatic fibrosis action and mechanism of natural products. International Immunopharmacology 75: 105765.

19. Lee, E.S., M.O. Shin, S. Yoon, and J.O. Moon. 2010. Resveratrol inhibits dimethyltrosamine-induced hepatic fibrosis in rats. Archives of Pharmacal Research 33: 925–932.

20. Chan, C.C., L.Y. Cheng, C.L. Lin, Y.H. Huang, H.C. Lin, and F.Y. Lee. 2011. The protective role of natural phytoalexin resveratrol on inflammation fibrosis and regeneration in cholestatic liver injury. Molecular Nutrition & Food Research 55: 1841–1849.

21. Yu, F., W. Geng, P. Dong, Z. Huang, and J. Zheng. 2018. LncRNA-MEG3 inhibits activation of hepatic stellate cells through SMO protein and miR-212. Cell Death & Disease 9: 1014.

22. Mencin, A., E. Seki, Y. Osawa, Y. Kodama, S. De Minicis, M. Knowles, and D.A. Brenner. 2007. Alpha-1 antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis. Hepatology 46: 1443–1452.

23. Huang, Y., X. Li, Y. Wang, H. Wang, C. Huang, and J. Li. 2014. Endoplasmic reticulum stress-induced hepatic stellate cell apoptosis through calcium-mediated JNK/P38 MAPK and Calpain/Caspase-12 pathways. Molecular and Cellular Biochemistry 394: 1–12.

24. Mu, Y.P., T. Ogawa, and N. Kawada. 2010. Reversibility of fibrosis, inflammation, and endoplasmic reticulum stress in the liver of rats fed a methionine-choline-deficient diet. Laboratory Investigation 90: 245–256.

25. Li, H., Q. Li, X. Zhang, X. Zheng, Q. Zhang, and Z. Hao. 2018. Thymosin beta4 suppresses CCl4-induced murine hepatic fibrosis by down-regulating transforming growth factor beta receptor-II. The Journal of Gene Medicine 20: e3043.

26. Tanjore, H., W.E. Lawson, and T.S. Blackwell. 2013. Endoplasmic reticulum stress as a pro-fibrotic stimulus. Biochimica et Biophysica Acta 1832: 940–947.

27. Yang, Z., J. Zhang, Y. Wang, J. Lu, and Q. Sun. 2021. Caveolin-1 deficiency protects mice against carbon tetrachloride-induced acute liver injury through regulating polarization of hepatic macrophages. Frontiers in Immunology 12: 713808.
28. Lee, S.H., S.I. Do, and H.S. Kim. 2014. Hyperoxia accelerates progression of hepatic fibrosis by up-regulation of transforming growth factor-beta expression. *World Journal of Gastroenterology* 20: 3011–3017.

29. Wang, H., J. Che, K. Cui, W. Zhuang, H. Li, J. Sun, J. Chen, et al. 2021. Schisantherin A ameliorates liver fibrosis through TGF-beta1 mediated activation of TAK1/MAPK and NF-kappaB pathways *in vitro* and *in vivo*. *Phytomedicine* 88: 153609.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.